NCT05970133 Robotic Versus Laparoscopy NOSE for Stage I-III Left-sided Colon Cancer
| NCT ID | NCT05970133 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Taiwan University Hospital |
| Condition | Colorectal Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 300 participants |
| Start Date | 2023-04-07 |
| Primary Completion | 2025-04-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 300 participants in total. It began in 2023-04-07 with a primary completion date of 2025-04-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In this project, the investigator aims to provide the level 1 evidence for the comparison of robotic versus laparoscopic NOSE for the surgery of stage I-III colorectal cancer. the investigator hypothesize that, with the increased maneuverability of the current robotic system, robotic surgery will be a good option for patients with stage I-III colorectal cancer requiring a NOSE procedure.
Eligibility Criteria
Inclusion Criteria: 1. Primary colon cancers located at the left sided colonic anatomic location, including distal transverse colon, colonic splenic flexure, descending colon, sigm oid descending colonic junction, sigmoid colon and upper rectum that required the mobilization of colonic splenic flexure to facilitate a curative resection and trans anal specimen extraction ; 2. TNM Stage I III adenocarcinomas; 3. Curative and elective surgery; 4. American Society of Anesthesiology (ASA) class I to III patients; 5. Age \>18 years. Exclusion Criteria: 1. Cecal, ascending, the proximal and middle transverse colon cancers; and the middle or lower rectal cancers; 2. Emergency or palliative surgery; 3. Evidence of disseminated disease or adjacent organ invasion; 4. Primary tumor mass \>8 cm in diameter; 5. Morbidly obese patients, that is, body mass index (BMI) ≥40 kg/m 2 ; 6. Previous major surgery of upper abdomen or pelvis
Contact & Investigator
Jin-Tung LIANG, MD
STUDY CHAIR
National Taiwan University Hospital
Frequently Asked Questions
Who can join the NCT05970133 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Colorectal Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05970133 currently recruiting?
Yes, NCT05970133 is actively recruiting participants. Contact the research team at jintung@ntu.edu.tw for enrollment information.
Where is the NCT05970133 trial being conducted?
This trial is being conducted at Taipei, Taiwan.
Who is sponsoring the NCT05970133 clinical trial?
NCT05970133 is sponsored by National Taiwan University Hospital. The principal investigator is Jin-Tung LIANG, MD at National Taiwan University Hospital. The trial plans to enroll 300 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.